Ferndale Laboratories, Inc. v. Cavendish

79 F.3d 488, 1996 U.S. App. LEXIS 4935
CourtCourt of Appeals for the Sixth Circuit
DecidedMarch 21, 1996
Docket94-4108
StatusPublished

This text of 79 F.3d 488 (Ferndale Laboratories, Inc. v. Cavendish) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ferndale Laboratories, Inc. v. Cavendish, 79 F.3d 488, 1996 U.S. App. LEXIS 4935 (6th Cir. 1996).

Opinion

79 F.3d 488

64 USLW 2604

FERNDALE LABORATORIES, INC., Plaintiff-Appellee,
v.
Robert B. CAVENDISH, R.Ph., Paul F. Lamping, R.Ph., Amonte
B. Littlejohn, R.Ph., Wayne C. Miller, R.Ph., Timothy D.
Moore, R.Ph., Suzanne L. Neuber, R.Ph., Ruth A. Plant,
R.Ph., Nicholas R. Repke, and Joseph R. Sabino, Jr., R.Ph.,
Members of the Ohio State Board of Pharmacy, Defendants-Appellants.

No. 94-4108.

United States Court of Appeals,
Sixth Circuit.

Argued Dec. 7, 1995.
Decided and Filed March 21, 1996.

On Appeal from the United States District Court for the Northern District of Ohio; John W. Potter, Judge.

Thomas A. Roach (argued and briefed), Lydia P. Loren, Bodman, Longley & Dahling, Ann Arbor, MI, for Plaintiff-Appellee.

Anne Berry Strait, Asst. Atty. Gen. (argued and briefed), Robert J. McClaren (briefed), Office of the Attorney General of Ohio, Columbus, OH, for Defendants-Appellants.

David C. Thollander, John F. Atkinson, and Dale J. Atkinson, Atkinson & Atkinson, Evanston, IL, for National Ass'ns of Boards of Pharmacy, Amicus Curiae.

Ray M. Aragon, Gary L. Yingling (briefed), McKenna & Cuneo, Washington, DC, for National Pharmaceutical Alliance, Amicus Curiae.

James N. Czaban (briefed), Bass & Ullman, New York City, for National Ass'n of Pharmaceutical Manufacturers, Amicus Curiae.

Before: LIVELY, KENNEDY, and RYAN, Circuit Jud ges.

LIVELY, Circuit Judge.

This appeal presents the question whether an Ohio statute that requires wholesale distributors of pharmaceuticals to register with and pay a license fee to the State of Ohio violates the Commerce Clause of the United States Constitution when applied to an out-of-state wholesale drug distributor. The district court held that the statute, as applied to a Michigan wholesale distributor, does violate the Commerce Clause, and entered an injunction against the state body charged with enforcing the statute.

I.

A.

The plaintiff, Ferndale Laboratories, Inc. (Ferndale), manufactures and distributes pharmaceuticals from its facilities in Michigan. It is licensed by the federal government and the State of Michigan as a manufacturer and wholesaler of prescription drugs. When the State of Ohio ordered one of Ferndale's Ohio customers to discontinue purchases from Ferndale until Ferndale registered under the statute in question, Ferndale applied for registration and paid the required fee ($100) under protest, then filed this action for declaratory and injunctive relief. The defendants are the members of the Ohio State Board of Pharmacy, the body that registers wholesale distributors of pharmaceuticals and other drugs, collects the registration fee, and administers the statute.

B.

The case was submitted to the district court on cross-motions for summary judgment, and the court granted summary judgment in favor of the plaintiff, Ferndale. Neither party contends that the case involves issues of material fact, or that the district court relied on erroneous factual findings. Accordingly, we adopt the district court's statement of the facts, as set forth in its unpublished opinion:

Plaintiff operates a wholesale pharmaceutical business based in Michigan whereby customers from across the country order prescription medications which are then shipped by plaintiff. Plaintiff's activities with regard to the State of Ohio include the distribution of samples to physicians and the sale of prescription drugs to wholesalers, hospitals, and some industrial entities. Plaintiff does not sell medication directly to consumers in Ohio. None of plaintiff's employees work in Ohio or travel to Ohio on plaintiff's behalf, nor does plaintiff own any tangible property in Ohio. Plaintiff is registered as a wholesale pharmaceutical distributor in Michigan and is therefore in compliance with Michigan and federal registration requirements. Defendant has not alleged that Michigan's regulations are substantially different from Ohio's.

Ohio Revised Code § 4729.51 provides, in pertinent part, that "[n]o person other than a registered wholesale distributor of dangerous drugs shall possess for sale, sell, distribute, or deliver, at wholesale, dangerous drugs."1 The registration procedure is contained in Ohio Rev.Code § 4729.52. Section 4729.52 provides that out-of-state wholesalers may be licensed as well as in-state wholesalers. Since the adoption of Section 4729.51, the Board has required both in-state and out-of-state wholesale distributors to register and pay a registration fee. The record reflects that the fee charged is currently $100.00 per year. There is no allegation or evidence that there has ever been a disparity in the fee charged to resident as opposed to nonresident wholesale distributors.

The instant case arose when plaintiff elected to not pay the Ohio registration fee. Subsequently, defendants determined that one of the plaintiff's customers was purchasing dangerous drugs from plaintiff, an unlicensed wholesaler. Section 4729.51(D) requires that terminal distributors of dangerous drugs purchase drugs only from wholesalers who register with the Board. This provision provides economic leverage for the Board to require out-of-state wholesalers to register in Ohio. After the Board ordered a terminal distributor to stop buying drugs from plaintiff because of plaintiff's refusal to register, plaintiff paid the registration fee under protest and instituted the present action.

II.

The defendants make two arguments on appeal. First, the defendants contend that in enacting a statute specifically regulating the wholesale distribution of drugs in 1987, Congress delegated the responsibility for regulating the wholesale distribution of prescription drugs to the states. See the Prescription Drug Marketing Act of 1987 (the Act), Pub.L. No. 100-293, codified at 21 U.S.C. § 353 (1988). They rely particularly on 21 U.S.C. § 353(e)(2)(A), which provides:

No person may engage in the wholesale distribution in interstate commerce of drugs subject to subsection (b) of this section in a State unless such person is licensed by the State in accordance with the guidelines issued under subparagraph (B).

The defendants construe the words "unless such person is licensed by the State" to be a broad delegation to the states of the power to regulate the wholesale distribution of drugs along with the power to require compliance by such wholesalers with federal, state and local drug laws.

Second, the defendants argue that in addition to the general delegation under the Act, Ohio has authority to regulate out-of-state wholesalers of dangerous drugs under its traditional police powers. As an activity that affects the general welfare of Ohio inhabitants, regulating the importation of dangerous drugs into the State is among those activities most clearly within a state's police power, according to the defendants.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gibbons v. Ogden
22 U.S. 1 (Supreme Court, 1824)
Shafer v. Farmers Grain Co. of Embden
268 U.S. 189 (Supreme Court, 1925)
Baldwin v. G. A. F. Seelig, Inc.
294 U.S. 511 (Supreme Court, 1935)
Bourjois, Inc. v. Chapman
301 U.S. 183 (Supreme Court, 1937)
Huron Portland Cement Co. v. City of Detroit
362 U.S. 440 (Supreme Court, 1960)
Pike v. Bruce Church, Inc.
397 U.S. 137 (Supreme Court, 1970)
Raymond Motor Transportation, Inc. v. Rice
434 U.S. 429 (Supreme Court, 1978)
City of Philadelphia v. New Jersey
437 U.S. 617 (Supreme Court, 1978)
Lewis v. BT Investment Managers, Inc.
447 U.S. 27 (Supreme Court, 1980)
Edgar v. Mite Corp.
457 U.S. 624 (Supreme Court, 1982)
Maine v. Taylor
477 U.S. 131 (Supreme Court, 1986)
Healy v. Beer Institute
491 U.S. 324 (Supreme Court, 1989)
Quill Corp. v. North Dakota Ex Rel. Heitkamp
504 U.S. 298 (Supreme Court, 1992)
Southern Pacific Co. v. Arizona Ex Rel. Sullivan
325 U.S. 761 (Supreme Court, 1945)
Ferndale Laboratories, Inc. v. Cavendish
79 F.3d 488 (Sixth Circuit, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
79 F.3d 488, 1996 U.S. App. LEXIS 4935, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ferndale-laboratories-inc-v-cavendish-ca6-1996.